Drug
Paclitaxel for Injection
Paclitaxel for Injection is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
recruiting4100%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07165951
recruitingphase_1
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07229586
recruitingphase_3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
NCT07111832
recruitingphase_2
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
NCT06123884
Clinical Trials (4)
Showing 4 of 4 trials
NCT07165951Phase 3
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT07229586Phase 1
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
NCT07111832Phase 3
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
NCT06123884Phase 2
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4